ArticleCancer medicine2025
METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- METTL14 modulates the nasopharyngeal carcinoma microenvironment via mFrontiers in immunology · 2026Article
- METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundNasopharyngeal carcinoma (NPC), highly prevalent in southern China, often leads to treatment failure in advanced stages due to recurrence or metastasis. While METTL14 plays a crucial role in cancer, its regulation of immune- and inflammation-related genes remains poorly understood. This study aims to investigate whether METTL14 is involved in regulating the expression of genes associated with tumor necrosis factor (TNF), interferon (IFN), interleukin (IL), and MHC class I in NPC cells.
methodsQuantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to examine METTL14 expression in NPC cells with either shMETTL14 knockdown or METTL14 overexpression. RNA sequencing was performed to identify differentially expressed genes associated with TNF, IFN, IL, and MHC class I in NPC cells, and qRT-PCR was used to validate the expression of these genes. A cytokine production assay was conducted to measure the levels of TNFSF9, IFI16, IL-6, IL-7, CXCL10, and HLA-B.
resultsOur study demonstrates that METTL14 potentially plays a fundamental role in modulating the expression of genes associated with TNF, IFN, IL, and MHC class I in NPC cells. RNA sequencing of NPC cells showed that METTL14 upregulated or downregulated several genes associated with immunity and inflammation, including TNF, IFN, IL, and MHC class I. RNA interference-mediated knockdown of METTL14 revealed its regulatory effects on TNF-related genes (e.g., TNFRSF12A, TNFRSF9, TNFSF15), IFN-induced genes (e.g., PSMC6, PSMD1, PSMA2, PSMA3, PSMB2), and IL-related genes (e.g., CCL5, IL1B, IL32, IL7R, IL6, IL7, CXCL2). Furthermore, METTL14 was found to positively regulate MHC class I gene expression (e.g., HLA-A, -B, -C, -E, -F) in NPC cells.
conclusionsThese findings demonstrate, for the first time, that METTL14 modulates the expression of genes related to TNF, IFN, IL, and MHC class I in NPC, proposing a novel role for METTL14 in linking inflammation with cancer, a function that has not been fully elucidated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.